adicet bios inc acet stock tumbled about 38 in premarket trading on monday after the company shared data from a phase 1 clinical trial evaluating the companys investigational cart therapy in patients with relapsed or refractory bcell nonhodgkins lymphoma its too early for a true overall response rate complete response and 6month cr rate but profile continues to be promising wedbush analysts told investors on monday morning adicet said it plans to move adi001 into a pivotal program in the second quarter of 2023 the companys stock is down 12 this year while the sp 500 spx has declined 165